CCR5 Antibodies HGS004 and HGS101 Preferentially Inhibit Drug-bound CCR5 Infection and Restore Drug Sensitivity of Maraviroc-resistant HIV-1 in Primary Cells

Overview

Journal Virology

Specialty Microbiology

Date 2011 Jan 15

PMID 21232779

Citations 11

Authors

Olga Latinovic

Marvin Reitz

Nhut M Le

James S Foulke

Gerd Fatkenheuer

Clara Lehmann

Robert R Redfield

Alonso Heredia

Affiliations

Soon will be listed here.

Abstract

R5 HIV-1 strains resistant to the CCR5 antagonist Maraviroc (MVC) can use drug-bound CCR5. We demonstrate that MVC-resistant HIV-1 exhibits delayed kinetics of coreceptor engagement and fusion during drug-bound versus free CCR5 infection of cell lines. Antibodies directed against the second extracellular loop (ECL2) of CCR5 had greater antiviral activity against MVC-bound compared to MVC-free CCR5 infection. However, in PBMCs, only ECL2 CCR5 antibodies HGS004 and HGS101, but not 2D7, inhibited infection by MVC resistant HIV-1 more potently with MVC-bound than with free CCR5. In addition, HGS004 and HGS101, but not 2D7, restored the antiviral activity of MVC against resistant virus in PBMCs. In flow cytometric studies, CCR5 binding by the HGS mAbs, but not by 2D7, was increased when PBMCs were treated with MVC, suggesting MVC increases exposure of the relevant epitope. Thus, HGS004 and HGS101 have antiviral mechanisms distinct from 2D7 and could help overcome MVC resistance.

Citing Articles

In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha.

Ashokkumar M, Sonawane A, Sperk M, Tripathy S, Neogi U, Hanna L Sci Rep. 2020; 10(1):2747.

PMID: 32066770 PMC: 7026412. DOI: 10.1038/s41598-020-59596-x.

CCR5 Inhibitors and HIV-1 Infection.

Latinovic O, Reitz M, Heredia A J AIDS HIV Treat. 2019; 1(1):1-5.

PMID: 31414081 PMC: 6693856. DOI: 10.33696/AIDS.1.001.

A novel small-molecule inhibitor of HIV-1 entry.

Heredia A, Latinovic O, Barbault F, de Leeuw E Drug Des Devel Ther. 2015; 9:5469-78.

PMID: 26491257 PMC: 4598220. DOI: 10.2147/DDDT.S89338.

Maraviroc: a review of its use in HIV infection and beyond.

Woollard S, Kanmogne G Drug Des Devel Ther. 2015; 9:5447-68.

PMID: 26491256 PMC: 4598208. DOI: 10.2147/DDDT.S90580.

Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies.

Latinovic O, Medina-Moreno S, Schneider K, Gohain N, Zapata J, Pazgier M AIDS Res Hum Retroviruses. 2015; 32(2):178-86.

PMID: 26059995 PMC: 4761833. DOI: 10.1089/AID.2015.0020.

References

Cooper D, Heera J, Goodrich J, Tawadrous M, Saag M, DeJesus E . Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010; 201(6):803-13. DOI: 10.1086/650697. View

Jacobson J, Lalezari J, Thompson M, Fichtenbaum C, Saag M, Zingman B . Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother. 2010; 54(10):4137-42. PMC: 2944554. DOI: 10.1128/AAC.00086-10. View

Demarest J, Amrine-Madsen H, Irlbeck D, Kitrinos K . Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob Agents Chemother. 2008; 53(3):1116-23. PMC: 2650552. DOI: 10.1128/AAC.01055-08. View

Pugach P, Ray N, Klasse P, Ketas T, Michael E, Doms R . Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology. 2009; 387(2):296-302. PMC: 2674391. DOI: 10.1016/j.virol.2009.02.044. View

Agrawal-Gamse C, Lee F, Haggarty B, Jordan A, Yi Y, Lee B . Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol. 2009; 83(21):11005-15. PMC: 2772790. DOI: 10.1128/JVI.01238-09. View

Berro R, Sanders R, Lu M, Klasse P, Moore J . Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009; 5(8):e1000548. PMC: 2718843. DOI: 10.1371/journal.ppat.1000548. View

Laakso M, Lee F, Haggarty B, Agrawal C, Nolan K, Biscone M . V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 2007; 3(8):e117. PMC: 1950945. DOI: 10.1371/journal.ppat.0030117. View

Reynes J, Portales P, Segondy M, Baillat V, Andre P, Reant B . CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis. 2000; 181(3):927-32. DOI: 10.1086/315315. View

Jacobson J, Saag M, Thompson M, Fischl M, Liporace R, Reichman R . Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis. 2008; 198(9):1345-52. DOI: 10.1086/592169. View

10.

Anastassopoulou C, Ketas T, Klasse P, Moore J . Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A. 2009; 106(13):5318-23. PMC: 2664029. DOI: 10.1073/pnas.0811713106. View

11.

Tsibris A, Sagar M, Gulick R, Su Z, Hughes M, Greaves W . In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol. 2008; 82(16):8210-4. PMC: 2519584. DOI: 10.1128/JVI.00444-08. View

12.

Gulick R, Su Z, Flexner C, Hughes M, Skolnik P, Wilkin T . Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007; 196(2):304-12. DOI: 10.1086/518797. View

13.

Hill C, Kwon D, Jones M, Davis C, Marmon S, Daugherty B . The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology. 1998; 248(2):357-71. DOI: 10.1006/viro.1998.9283. View

14.

Alkhatib G, Combadiere C, Broder C, Feng Y, Kennedy P, Murphy P . CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996; 272(5270):1955-8. DOI: 10.1126/science.272.5270.1955. View

15.

Wilkin T, Su Z, Krambrink A, Long J, Greaves W, Gross R . Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2010; 54(5):470-6. PMC: 2917795. DOI: 10.1097/qai.0b013e3181e2cba0. View

16.

Tsibris A, Korber B, Arnaout R, Russ C, Lo C, Leitner T . Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One. 2009; 4(5):e5683. PMC: 2682648. DOI: 10.1371/journal.pone.0005683. View

17.

Nolan K, Del Prete G, Jordan A, Haggarty B, Romano J, Leslie G . Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J Virol. 2009; 83(8):3798-809. PMC: 2663279. DOI: 10.1128/JVI.01751-08. View

18.

Cocchi F, Devico A, Garzino-Demo A, Arya S, Gallo R, Lusso P . Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995; 270(5243):1811-5. DOI: 10.1126/science.270.5243.1811. View

19.

Sougrat R, Bartesaghi A, Lifson J, Bennett A, Bess J, Zabransky D . Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog. 2007; 3(5):e63. PMC: 1864992. DOI: 10.1371/journal.ppat.0030063. View

20.

Reeves J, Gallo S, Ahmad N, Miamidian J, Harvey P, Sharron M . Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A. 2002; 99(25):16249-54. PMC: 138597. DOI: 10.1073/pnas.252469399. View